Ipramol

Ipratropium bromide / Salbutamol, the active ingredients in Ipramol, constitute a bronchodilator (combination anticholinergic and β2‑agonist) presented as a combination formulation for inhalation and oral administration. It helps relieve bronchoconstriction and improve airflow in patients with asthma and chronic obstructive pulmonary disease (COPD).

GNH USA supplies Ipramol as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide from its EU‑origin market. The company adheres to stringent quality standards and supports global distribution networks. All shipments are accompanied by full regulatory documentation.

Ipramol, a combination bronchodilator, is used to manage obstructive airway diseases by relaxing airway smooth muscle. - Asthma: improves airflow and reduces symptoms such as wheezing and shortness of breath. - Chronic obstructive pulmonary disease (COPD): alleviates chronic bronchoconstriction and enhances exercise tolerance. - Acute bronchospasm: provides rapid bronchodilation during sudden airway narrowing episodes.

Ipramol may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dry mouth. - Tremor or shakiness. - Headache. - Throat irritation or cough. - Palpitations.

Serious or Rare Side Effects: - Paradoxical bronchospasm. - Significant tachycardia or arrhythmia. - Allergic reactions such as rash, angioedema, or anaphylaxis.

Use Ipramol with clinical caution and monitor patients for specific concerns. - Dose adjustment in renal impairment: monitor for accumulation and possible increased anticholinergic effects. - Cardiovascular disease: use carefully as the β2‑agonist component may raise heart rate and blood pressure. - Narrow‑angle glaucoma: anticholinergic action can increase intra‑ocular pressure; avoid in susceptible patients. - Pregnancy and breastfeeding: safety not established; prescribe only if benefit outweighs potential risk. - Drug interactions: review concomitant β‑agonists or anticholinergics to prevent additive effects. - Store at ambient temperature: keep in the original container, protect from moisture and heat, and store below 25 °C.

Ipramol can interact with several medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid): - MAO inhibitors: may precipitate hypertensive crisis. - Non‑selective beta‑blockers: can diminish bronchodilator efficacy and provoke bronchospasm. - Tricyclic antidepressants: increased anticholinergic load may exacerbate dry mouth and urinary retention.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypokalemia when combined with β2‑agonist. - Theophylline: additive tachycardia and tremor risk. - Other anticholinergic agents: may increase dryness of mucous membranes.